Using localized chemotherapy to boost the immune response against brain tumors
Generating a Systemic Immune Response Using Localized Delivery of Chemotherapy in Brain Tumors
This study is looking at how giving chemotherapy directly to the brain tumor can help boost the immune system's ability to fight glioblastoma, and it’s designed for patients with this type of brain cancer who want to explore new treatment options that might have fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10850828 on NIH RePORTER |
What this research studies
This research investigates how localized delivery of chemotherapy can enhance the immune response in patients with glioblastoma, a type of brain tumor. By combining local chemotherapy with immune checkpoint inhibitors, the study aims to overcome the tumor's ability to evade the immune system. The approach focuses on understanding the mechanisms of immune evasion and identifying potential biomarkers that could predict patient responses to treatment. Patients may receive localized chemotherapy directly at the tumor site, which could minimize side effects compared to traditional systemic chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with non-brain tumors or those who are not eligible for localized chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better immune responses in patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches in other cancer types, indicating potential for success in glioblastoma as well.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Lim, Michael — Stanford University
- Study coordinator: Lim, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.